David Krempa Sells 10,223 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 10,223 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $14.73, for a total value of $150,584.79. Following the transaction, the insider now directly owns 612,646 shares in the company, valued at $9,024,275.58. This trade represents a 1.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

David Krempa also recently made the following trade(s):

• On Friday, June 13th, David Krempa sold 6,800 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.77, for a total value of $100,436.00.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total value of $253,296.84.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON opened at $13.70 on Thursday. The stock has a fifty day moving average price of $16.63 and a 200-day moving average price of $15.03. The company has a market cap of $367.43 million, a price-to-earnings ratio of -76.11 and a beta of 1.28. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97. Eton Pharmaceuticals, Inc. has a fifty-two week low of $3.18 and a fifty-two week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. As a group, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Mink Brook Asset Management LLC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth $6,071,000. Cannell Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth $5,079,000. Millennium Management LLC lifted its position in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after buying an additional 217,042 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Eton Pharmaceuticals by 61.9% during the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company’s stock worth $5,219,000 after buying an additional 153,923 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Eton Pharmaceuticals by 230.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock worth $2,862,000 after buying an additional 149,864 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ETON has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $35.00 price target (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Finally, B. Riley reiterated a “buy” rating and set a $26.00 target price (up from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.